Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
0.328 CHF
21.24 M CHF
298.80 M CHF
142.92 M
About TG Therapeutics, Inc.
Sector
Industry
CEO
Michael Sean Weiss
Website
Headquarters
Morrisville
Founded
1993
ISIN
US88322Q1085
FIGI
BBG00LVGH2Q2
TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.
Related stocks
Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of NKB2 is 31.169 CHF — it has increased by 5.30% in the past 24 hours. Watch TG Therapeutics, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on BX exchange TG Therapeutics, Inc. stocks are traded under the ticker NKB2.
We've gathered analysts' opinions on TG Therapeutics, Inc. future price: according to them, NKB2 price has a max estimate of 43.26 CHF and a min estimate of 8.65 CHF. Watch NKB2 chart and read a more detailed TG Therapeutics, Inc. stock forecast: see what analysts think of TG Therapeutics, Inc. and suggest that you do with its stocks.
NKB2 reached its all-time high on Jun 25, 2021 with the price of 35.801 CHF, and its all-time low was 0 CHF and was reached on Jun 25, 2021. View more price dynamics on NKB2 chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
NKB2 stock is 5.03% volatile and has beta coefficient of 0.21. Track TG Therapeutics, Inc. stock price on the chart and check out the list of the most volatile stocks — is TG Therapeutics, Inc. there?
Today TG Therapeutics, Inc. has the market capitalization of 4.40 B, it has decreased by −14.21% over the last week.
Yes, you can track TG Therapeutics, Inc. financials in yearly and quarterly reports right on TradingView.
TG Therapeutics, Inc. is going to release the next earnings report on Oct 30, 2025. Keep track of upcoming events with our Earnings Calendar.
NKB2 earnings for the last quarter are 0.13 CHF per share, whereas the estimation was 0.17 CHF resulting in a −19.49% surprise. The estimated earnings for the next quarter are 0.17 CHF per share. See more details about TG Therapeutics, Inc. earnings.
TG Therapeutics, Inc. revenue for the last quarter amounts to 111.99 M CHF, despite the estimated figure of 109.48 M CHF. In the next quarter, revenue is expected to reach 120.20 M CHF.
NKB2 net income for the last quarter is 22.36 M CHF, while the quarter before that showed 4.48 M CHF of net income which accounts for 399.26% change. Track more TG Therapeutics, Inc. financial stats to get the full picture.
No, NKB2 doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Sep 23, 2025, the company has 338 employees. See our rating of the largest employees — is TG Therapeutics, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. TG Therapeutics, Inc. EBITDA is 68.30 M CHF, and current EBITDA margin is 12.83%. See more stats in TG Therapeutics, Inc. financial statements.
Like other stocks, NKB2 shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade TG Therapeutics, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So TG Therapeutics, Inc. technincal analysis shows the buy rating today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating TG Therapeutics, Inc. stock shows the buy signal. See more of TG Therapeutics, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.